NCT06954662CompletedEarly phase 1
A Targeted Amino Acid Supplement for People With Parkinson's Disease
Comparison of Whey Protein and Amino Acid Supplementation on Amino Acid and Levodopa Concentrations in People With Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. The main question it aims to answer is: • Does an amino acid supplement that is specifically made for people with Parkinson disease have short-term improvements in nutrition deficiencies, while minimally interfering with Parkinson disease medication? Researchers will compare the short-term effects of this specialized nutrition supplement to a supplement that is available for everyone to purchase in a store (whey protein supplement-a milk by-product) and to an inactive supplement. Researchers will then check for the indicators of nutrition levels and the presence of dopamine medication in the blood. Researchers will also assess mood and movement abilities in participants. Participants will be asked to: * attend 4 study visits over the course of 4 weeks (initial orientation visit plus 3 intervention visits). * drink one of the 3 supplements (supplements will be mixed into water to create a beverage) at each of the 3 intervention visits. * participate in blood drawings and mood and movement assessments at each of the intervention visits. * engage in a phone call after each intervention visit to determine any delayed responses.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 28 Mar 2025
- Start date
- 22 May 2025
- Primary completion date
- 17 Jul 2025
- Lead sponsor
- UConn Health
- Diseases
- Parkinson disease
- NCT number
- NCT06954662
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 3
- From 22 May 2025 to the primary completion date, 17 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any known bleeding disorder or currently taking blood thinners
- Gastric or bowel resection surgery
Other illness
- Apparent cognitive impairment as determined by phone screening (TICS)
- Diagnosis of Parkinsonism or atypical Parkinson's Disease
- Any unstable medical condition
Other
- Are prescribed a dopamine antagonist
- Using deep brain stimulation
Who the study is looking for
- diagnosis of idiopathic Parkinson disease by patient report
- 55 years or older
- Has been using dopamine replacement medication (e.g. levodopa) for at least 2 years.
- On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UConn Health, Clinical Research Center Coordinator of this site? Confirm its status | Farmington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.